Global VMAT2 Inhibitors Market, By Application (Huntington’s Disease, Tardive Dyskinesia, Other), Drugs (Tetrabenazine, Deutetrabenazine, Valbenazine, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
VMAT2 Inhibitors Market Analysis and Size
Increasing cases of tardive dyskinesia and Huntington’s disease boosts the VMAT2 inhibitors market. The global incidence of Parkinson's disease is expected to be about 6.1 million worldwide which demand the wide use of these inhibitors. Most of the well-known companies in the global market are primarily focused on investing readily on developing therapeutics for several mental disorders which will lead to the market's growth.
Data Bridge Market Research analyses a growth rate in VMAT2 inhibitors market in the forecast period 2023-2030. The expected CAGR of VMAT2 inhibitors market tend to be around 7% in the mentioned forecast period. The market value is USD 44 billion in 2022, and it would grow upto USD 75.60 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
VMAT2 Inhibitors Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Application (Huntington’s Disease, Tardive Dyskinesia, Other), Drugs (Tetrabenazine, Deutetrabenazine, Valbenazine, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Neurocrine Biosciences, Inc (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India), Hikma Pharmaceuticals plc (U.K.), Hetero (India), Bausch Health Companies Inc. (Canada), Dr. Reddy’s Laboratories Ltd(India), Piramal Pharma Solutions (India), and Lupin (India)
|
|
Market Opportunities
|
|
Market Definition
Vesicular monoamine transporter-2 is the transmembrane protein which is primarily responsible for the transport of monoamines neurotransmitters such as histamines, serotonin, dopamine, and norepinephrine into the synaptic vesicles. VMAT2 transporter carries the cytoplasmic dopamine into the vesicles. VMAT2 inhibitors reduce the dopamine at the presynaptic striatal nerve terminals and decrease unwanted body movements for these conditions. VMAT2 inhibitors are widely used to treat uncontrollable involuntary, repetitive body movements caused by tardive dyskinesia and Huntington’s disease.
VMAT2 Inhibitors Market Dynamics
Drivers
- Increased Prevalence of Huntington’s Disease
Huntington’s disease is a type of brain disorder that causes involuntary body movement, loss of recognition ability, and emotional problems. Incidence of this disease is high in the developed countries, particularly in Europe. An estimated 5 to 7 people per 100,000 are majorly affected by this disease in countries in the West. Increased prevalence of Huntington’s disease has been witnessed in Venezuela, where about 700 people per 100,000 have the disease. In the U.S., this disease is prevalent in 15% to 30% patients who have received long-term neuroleptic medication.
- Increasing Prevalence of Product Approvals
Numerous product approvals in VMAT inhibitors are increasing the growth of the market. For instance, Neurocrine Biosciences presented new INGREZZA (valbenazine) data on tardive dyskinesia improvement and stability of psychiatric symptoms at the American Psychiatric Association Annual Meeting 2022 in May 2022. Such developments are anticipated to drive the tardive dyskinesia treatment market.
Opportunities
- Increased Prevalence of Parkinson’s Disease
VMAT is anticipated to witness healthy growth in the future due to the increasing number of neurological disorders and rising antipsychotic prescriptions. According to the research article “Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future” published in February 2022, the prevalence of Parkinson's disease is projected to be around 6.1 million worldwide, and the incidence increases with age, reaching 1% to 3% in the population over 65 years of age,. In addition to this, the data updated by World Health Organization in October 2021 revealed that by 2030, 1 in 6 people in the world will be aged 60 years or over. Thus, this factor significantly increases the market growth as it will increase the demand of these inhibitors.
Restraints/Challenges
- Side Effects of VMAT2 inhibitors
There are varied adverse effects associated with VMAT2 inhibitors which impede the market growth. Common side effects include sedation, somnolence, fatigue, insomnia, restlessness (akathisia), agitation, depression, and nausea. The symptoms that rarely observed are suicidality, symptomatic hypotension, severe depression, prolongation of the QTc interval and neuroleptic malignant syndrome. This increasing side effects will obstruct the market growth.
This VMAT2 inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the VMAT2 inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2022, Neurocrine Biosciences presented new INGREZZA (valbenazine) data on tardive dyskinesia improvement and stability of psychiatric symptoms at the American Psychiatric Association Annual Meeting 2022
- In 2021, Teva Pharmaceuticals, which is a subsidiary of Teva Pharmaceutical Industries Ltd. in the U.S., released the results of a post hoc analysis of a long-term, three-year open-label extension (OLE) study evaluating the efficacy and safety endpoints for the use of AUSTEDO (Deutetrabenazine) tablets in younger (55 years) and older (55 years) patients with tardive dyskinesia (TD).
Global VMAT2 Inhibitors Market Scope
The VMAT2 inhibitors market is segmented on the basis of application, drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
- Huntington’s Disease
- Tardive Dyskinesia
- Other
Drugs
- Tetrabenazine
- Deutetrabenazine
- Valbenazine
- Others
Route of Administration
- Oral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
VMAT2 Inhibitors Market Regional Analysis/Insights
The VMAT2 inhibitors market is analyzed and market size insights and trends are provided by application, drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the VMAT2 inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for VMAT2 inhibitors market throughout the forecast period due to the increased incidence of huntington’s disease and tardive dyskinesia disease.
North America dominates the market due to the growing aging population, increased incidence of schizophrenia, growing awareness, growing healthcare expenditure, and the increasing presence of well-established healthcare infrastructure. The aging population will be causing many diseases associated with mental health for which this population has to take these inhibitors, thus enhancing the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global VMAT2 Inhibitors Market Share Analysis
The VMAT2 inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related VMAT2 inhibitors market.
Key players operating in the VMAT2 inhibitors market include:
- Neurocrine Biosciences, Inc (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sun Pharmaceutical Industries Ltd. (India)
- Hikma Pharmaceuticals plc (U.K.)
- Hetero (India)
- Bausch Health Companies Inc.(Canada)
- Dr. Reddy’s Laboratories Ltd. (India)
- Piramal Pharma Solutions (India)
- Lupin (India)
SKU-